John Jagerson and Wade Hansen

John Jagerson and Wade Hansen

Recent Articles

Trade of the Day: Teva Pharmaceuticals (TEVA) and Mylan (MYL)

By John Jagerson and Wade Hansen

Recent price shocks in biotech stocks is a good example of the risks investors may be exposed to as healthcare continues to become more complicated.

Best Stocks Update: XLF Has Room to Grow

By John Jagerson and Wade Hansen

Our Best Stocks for 2014 pick is the Financial SPDR (XLF), up over 2% year-to-date. Financials are performing well, and XLF should head higher in 2014.

Trade of the Day: Lorillard (LO)

By John Jagerson and Wade Hansen

Projected to grow 5-fold to by 2017 , the U.S. market for e cigarette brands is important but exposure to the international market is even more critical.

Stop Stressing Out About JPMorgan and Buy Now

By John Jagerson and Wade Hansen

JPMorgan Chase (JPM) should pass the Fed's evaluation with flying colors and extra capital.

Actavis Prescribes Profits via M&A and Generic Drugs

By John Jagerson and Wade Hansen

This specialty pharmaceutical company is consolidating its way into becoming a post-Affordable Care Act powerhouse.

Load More